Author

M. Pomerantz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

J.-H. Seo· 2 shared L. Ellis· 2 shared M. Freedman· 2 shared M. L. Freedman· 2 shared A. Bosma-Moody· 1 shared A. Dall'Agnese· 1 shared A. Farago· 1 shared A. Flaifel· 1 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J.-H. Seo

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Allele-specific epigenetic activity in prostate cancer and normal prostate tissue implicates prostate cancer risk mechanisms

A. Shetty, J.-H. Seo, C. A. Bell, E. P. O'Connor, M. Pomerantz, M. L. Freedman, A. Gusev

This study identifies allele-specific epigenetic activity in prostate cancer and normal tissue, linking it to GWAS risk loci and highlighting tumor-specific regulatory elements.

bioRxiv · Jun 2, 2021Cancer Biology

Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer

P. Cejas, Y. Xie, A. Font-Tello, K. Lim, S. Symala, X. Qiu, A. Tewari, N. Shah, H. Nguyen, R. Patel, L. Brown, I. Coleman, W. M. Hackeng, L. Brosens, K. Dreijerink, , H. W. Long

This study identifies two distinct subtypes of neuroendocrine prostate cancer based on neuronal transcription factors and highlights their epigenetic convergence and therapeutic implications.

bioRxiv · Sep 13, 2020Cancer Biology

Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint Inhibitors

Z. Bakouny, D. A. Braun, S. A. Shukla, W. Pan, X. Gao, Y. Hou, A. Flaifel, S. Tang, A. Bosma-Moody, M. X. He, N. Vokes, J. Nyman, W. Xie, A. H. Nassar, S. Abou Alaiwi, , T. H. Ho

This study characterizes the molecular features and immune profile of sarcomatoid and rhabdoid renal cell carcinoma, showing their responsiveness to immune checkpoint inhibitors and identifying key genetic and transcriptional determinants.

bioRxiv · May 28, 2020Cancer Biology

Genomic aberration based molecular signatures efficiently characterize homologous recombination deficiency in prostate cancer

Z. Sztupinszki, M. Diossy, M. Krzystanek, J. Borcsok, M. Pomerantz, V. Tisza, S. Spisak, O. Rusz, I. Csabai, M. Freedman, Z. Szallasi

The paper identifies genomic aberration-based molecular signatures to detect homologous recombination deficiency in prostate cancer, finding that 5-8% of cases may benefit from PARP-inhibitor treatment.

bioRxiv · Jun 24, 2019 · PreprintCancer Biology